OMB approves only the field test, including an incentive experiment, at this time. No specific incentive structure is pre-approved for the first wave of PATH (i.e., the baseline for the full study). After the field test has been completed but before commencing the first wave of data collection, NIH must submit a non-substantive change that clearly justifies the structure of incentives, addresses OMB concerns regarding the wording for some survey items, and otherwise ensures that the protocol and instruments maximize the utility of the data collection, minimize burden on participants, avoid duplication with existing Federal surveys, and comply with HHS data standards. If NIH plans to make significant changes (e.g., to the sample design) a full revision may be necessary.
Inventory as of this Action
Requested
Previously Approved
11/30/2015
36 Months From Approved
450,546
0
0
121,572
0
0
0
0
0
The NIH, through NIDA, is partnering with FDA's newly established Center for Tobacco Products (CTP) in a large-scale collaboration to conduct the PATH study. This national longitudinal study of tobacco use and health will provide epidemiological, population-based data about attitudes and perceptions related to the use of different existing and emerging tobacco products; patterns and trends in use of existing and emerging tobacco products; knowledge of the contents of tobacco products and of the consequences of their use; and on near- and longer-term health outcomes associated with tobacco product use. These data will advance the scientific knowledge base on tobacco use behaviors and health. In addition, the longitudinal component will serve to establish a science framework for FDA to track the potential behavioral and health impacts of specific FSPTCA-related smoking prevention programs as well as informing the development of new programs and policies. It will be the only national longitudinal study of tobacco use. As such, this study provides a unique opportunity to monitor and assess changes over time in patterns of use of tobacco products among study respondents. The study will collect national longitudinal survey data from a cohort of approximately 59,587 current, former, and never tobacco product users ages 12 years and older in the U.S. Biospecimens will also be collected from adult respondents to assess objective measures of exposure and prospectively monitor indicators of tobacco use-related harm.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.